RESUMO
BACKGROUND: More than 50% of adults report to suffer from sensitive skin. This common condition is characterized by subjective sensations such as prickling, burning, skin tightness or pruritus, and is often accompanied by objective symptoms like inflammation and erythema. OBJECTIVE: The objective of this study was to develop an active ingredient concept for the treatment of sensitive skin. We tested compounds regarding their potential to (i) decrease the release of proinflammatory mediators, which among others induce erythema and (ii) counteract the hyperresponsiveness of nerve fibres and, thus, exert effects on cutaneous neurosensory dysfunction. METHODS: 4-t-butylcyclohexanol, licochalcone A and acetyl dipeptide-1 cetyl ester were analysed in vitro regarding their potential to (i) decrease the release of PGE2 and activation of NFκB and to (ii) inhibit TRPV1 activation or the release of neuronal CGRP. To assess subjective and objective symptoms of skin sensitivity in vivo, two controlled, single-blind, randomized studies were conducted with 4-t-butylcyclohexanol and the combination with licochalcone A. RESULTS: In vitro, 4-t-butylcyclohexanol significantly reduced TRPV1 activation, while acetyl dipeptide-1 cetyl ester had no effect on receptor activation. Licochalcone A significantly decreased NFκB signalling and PGE2 secretion, at lower concentrations than acetyl dipeptide-1 cetyl ester. A formulation containing 4-t-butylcyclohexanol showed a significant immediate anti-stinging/anti-burning effect in vivo, and a cream base containing a combination of 4-t-butylcyclohexanol and a licochalcone A-rich licorice extract reduced shaving-induced erythema. CONCLUSION: In vitro and in vivo data indicate that the combination of the TRPV1 antagonist 4-t-butylcyclohexanol and the potent anti-inflammatory licochalcone A provide an effective active ingredient concept for the treatment of sensitive skin, as the topical application resulted in an immediate relief from symptoms such as erythema and stinging.
Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Chalconas/uso terapêutico , Cicloexanóis/uso terapêutico , Dermatoses Faciais/tratamento farmacológico , Dor/tratamento farmacológico , Transtornos de Sensação/tratamento farmacológico , Canais de Cátion TRPV/antagonistas & inibidores , Adulto , Animais , Anti-Inflamatórios não Esteroides/farmacologia , Peptídeo Relacionado com Gene de Calcitonina/metabolismo , Capsaicina/farmacologia , Linhagem Celular , Chalconas/farmacologia , Cicloexanóis/farmacologia , Dinoprostona/metabolismo , Dipeptídeos/farmacologia , Relação Dose-Resposta a Droga , Combinação de Medicamentos , Eritema/induzido quimicamente , Eritema/tratamento farmacológico , Dermatoses Faciais/induzido quimicamente , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , NF-kappa B/efeitos dos fármacos , NF-kappa B/metabolismo , Neurônios/efeitos dos fármacos , Neurônios/metabolismo , Dor/induzido quimicamente , Transtornos de Sensação/induzido quimicamente , Transdução de Sinais/efeitos dos fármacos , Método Simples-Cego , Creme para a Pele/uso terapêutico , Suínos , Canais de Cátion TRPV/metabolismo , Adulto JovemRESUMO
Recent double-blind controlled studies show that the application of a neomycin-bacitracin-polymyxin preparation reduces the incidence of staphylococcal and streptococcal infection of minor skin trauma. Allergic sensitization to neomycin is rare. Systemic side effects occur only with improper massive exposure. Resistant strains have appeared only in "closed populations." It is concluded that topical antibiotic combinations are safe and effective.
Assuntos
Bacitracina/uso terapêutico , Neomicina/uso terapêutico , Polimixinas/uso terapêutico , Pele/lesões , Infecção dos Ferimentos/prevenção & controle , Administração Tópica , Dermatite de Contato/etiologia , Método Duplo-Cego , Resistência Microbiana a Medicamentos , Quimioterapia Combinada , Estudos de Avaliação como Assunto , Glomerulonefrite/prevenção & controle , Humanos , Neomicina/efeitos adversos , Medicamentos sem Prescrição , Dermatopatias Infecciosas/prevenção & controle , Infecções Estafilocócicas/prevenção & controle , Infecções Estreptocócicas/prevenção & controle , Streptococcus pyogenesRESUMO
In much the same way as the survival of many species depends upon their abundant production of such genetic materials as pollens and spermatozoa, so does scientific progress depend upon a continual, lavish production of basic scientific works. In stimulating assembling, and disseminating various scientific studies related to the skin, the Montagna Symposia on the Biology of Skin have ensured progress not only in the understanding and management of skin was, is, and probably will always will be one of the richest sources of basic biologic information. No scientific discovery is wasted, no accurate clinical observation useless. No one can foresee when or how some seemingly irrelevant discovery in pure science or some seemingly insignificant clinical observation will yield fruits of incalculable practicable value. We cite here a few examples of some of the best results from apparently unrelated research and isolated clinical findings. In dermatologic research, the circular rhythm from patient with cutaneous disease to laboratory and from laboratory back to patient creates a centrifugal force that often spins off valuable discoveries.
Assuntos
Fenômenos Fisiológicos da Pele , Animais , HumanosRESUMO
The enigmas of why acne usually starts and stops at certain ages, why and how it so often cures itself, are recalled and some explanatory hypotheses are mentioned. Certain other enigmas are mentioned including why some patients have much oil and little acne, and some vice versa; why some blackheads and whiteheads initiate inflammation and suppuration and others not; why cysts and why scars form in some patients and not in others. Enigmas such as these show that acne is not only a common disease that supplies the practitioner's bread and butter, but one offering almost unequaled opportunities for research.
